NCT01732861 is a Phase 1 clinical trial of CC-292 in Leukemia Lymphocytic Chronic B-Cell, sponsored by Celgene.

Who is sponsoring NCT01732861?

NCT01732861 is sponsored by Celgene.

What drugs are being tested in NCT01732861?

Interventions in NCT01732861: CC-292, Lenalidomide.

What condition does NCT01732861 study?

NCT01732861 studies Leukemia Lymphocytic Chronic B-Cell.

Is NCT01732861 still recruiting?

NCT01732861 is currently completed. Last updated 20 December 2019.

Last reviewed 2019-12-20 · How we verify

NCT01732861

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Completed Phase 1 Last updated 20 December 2019

What this trial tests

Phase 1 trial testing CC-292 in Leukemia Lymphocytic Chronic B-Cell in 20 participants. Completed in 23 January 2019.

Timeline

28 December 2012

Primary endpoint
23 January 2019

23 January 2019

Quick facts

Lead sponsor	Celgene
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	28 December 2012
Primary completion	23 January 2019
Estimated completion	23 January 2019
Sites	11 locations across Austria, United States

Drugs / interventions tested

CC-292 — full drug profile →
Lenalidomide — full drug profile →

Conditions studied

Leukemia Lymphocytic Chronic B-Cell — all drugs for Leukemia Lymphocytic Chronic B-Cell →

Sponsor

Celgene — full company profile →

Who can join

18 and older, any sex, with Leukemia Lymphocytic Chronic B-Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a dose finding study using a 3 + 3 dose escalation and expansion design to determine a Not Tolerated Dose (NTD), Optimal Biological Effect Dose (OBE) and / or Maximum Tolerated Dose (MTD). These data will be used to establish a Recommended Phase 2 Dose (RP2D) for the combination of CC-292 and lenalidomide in subjects with Chronic Lymphocytic Leukemia (CLL).

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
Zhong L, Li Y, Xiong L, Wang W, et al · · 2021 · cited 1003× · PMID 34054126 · DOI 10.1038/s41392-021-00572-w
Ibrutinib and novel BTK inhibitors in clinical development.
Akinleye A, Chen Y, Mukhi N, Song Y, et al · · 2013 · cited 176× · PMID 23958373 · DOI 10.1186/1756-8722-6-59
Small Molecule NF-κB Pathway Inhibitors in Clinic.
Ramadass V, Vaiyapuri T, Tergaonkar V. · · 2020 · cited 154× · PMID 32708302 · DOI 10.3390/ijms21145164
Trial Watch: Lenalidomide-based immunochemotherapy.
Semeraro M, Vacchelli E, Eggermont A, Galon J, et al · · 2013 · cited 46× · PMID 24482747 · DOI 10.4161/onci.26494
The TKI Era in Chronic Leukemias.
De Novellis D, Cacace F, Caprioli V, Wierda WG, et al · · 2021 · cited 12× · PMID 34959482 · DOI 10.3390/pharmaceutics13122201
B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292.
Arnason JE, Brown JR. · · 2014 · cited 7× · PMID 27471698 · DOI 10.2147/itt.s37419

Verify or expand the search:

Other trials of CC-292

Trials testing the same drug.

NCT02433457 — Relative Bioavailability Study of CC-292 · Phase 1 · completed
NCT02031419 — Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma · Phase 1 · terminated

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01732861 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 20 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01732861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing